SAN DIEGO, Sept. 11, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.
Data from the study titled, "A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors" will be presented during the "Early Drug Development" poster session on Sunday, September 27, 2015 from 4:45 – 6:45 PM CEST/7:45 – 9:45 AM PDT at the Messe Wien Exhibition and Congress Centre, Hall C.
"MGCD516 is a potent, orally bioavailable inhibitor of key pathways that drive tumor growth. Specifically, MGCD516 targets driver mutations including RET, Trk and DDR gene alterations, which occur most often in patients with non-small cell lung cancer," said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. "In this dose escalation phase, MGCD516 was well tolerated and showed favorable PK characteristics in unselected cancer patients. Later this year we will begin treating selected patients with solid tumors, including non-small cell lung cancer."
About MGCD516
MGCD516 is a tyrosine kinase inhibitor that has demonstrated potent inhibition of a closely related spectrum of tyrosine kinases including RET, Trk and DDR, which are key regulators of signaling pathways that lead to cell growth, survival and tumor progression. These kinases and their key regulatory pathways are genetically altered in multiple cancer indications and act as oncogenic drivers that promote cancer development and progression in solid tumors, including non-small cell lung cancer (NSCLC). MGCD516 is in a Phase 1 dose escalation study in advanced solid tumors with an initial focus on NSCLC. Mirati retains worldwide rights to MGCD516.
About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished targeted oncology leadership team. The Mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.
Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, contain "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties. For more detailed disclosures and discussions regarding such forward looking statements, please refer to Mirati's filings with the U.S. Securities and Exchange Commission ("SEC"), including without limitation Mirati's filings on Forms 10-K, 10-Q, and 8-K. Forward looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology, or by statements that certain actions, events or results "may" or "would" be taken, occur or be achieved. Such statements include, but are not limited to, statements regarding Mirati's development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati's product candidates. Forward looking statements involve significant risks and uncertainties and are neither a prediction nor a guarantee that future events or circumstances will occur. Such risks include, but are not limited to, potential delays in development timelines or negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks described in Mirati's filings with the SEC. We are including this cautionary note to make applicable, and to take advantage of, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The information in this news release is given as of the date above and Mirati expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
Company Contact:
Anne Erickson
Mirati Therapeutics Inc.
Investor Relations and Corporate Communications
858-332-3532
ericksona@mirati.com
Investor Relations and Media Relations:
Jason Spark
Canale Communications
619-849-6005
jason@canalecomm.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-clinical-data-at-the-european-society-for-medical-oncology-esmo-2015-european-cancer-congress-300141372.html
SOURCE Mirati Therapeutics, Inc.
